NEW YORK (GenomeWeb) – Epigenomics announced today that it has received CE-IVD marking for its blood-based lung cancer test Epi proLung.

Epi proLung searches for a combination of DNA methylation biomarkers in order to detect cancer, the company said. The assay was partly developed with funding from the European Commission within the framework of the Horizon 2020 program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.